Expertise in
34
conditions

Dr. Misbah U. Qadir

Hematology | Oncology
ECU Health Cancer Care - Eddie And Jo Allison Smith Tower At ECU Health Medical Center
524 Moye Blvd, 
Greenville, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
34
conditions
ECU Health Cancer Care - Eddie And Jo Allison Smith Tower At ECU Health Medical Center
524 Moye Blvd, 
Greenville, NC 

Overview

Misbah Qadir is a Hematologist and an Oncologist practicing medicine in Greenville, North Carolina.

Dr. Qadir is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Colorectal Cancer, and Endoscopy.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 49 clinical trials. Dr. Qadir is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NC

Hospital Affiliations

Ecu Health Medical Center
The Outer Banks Hospital, Inc
Vidant Roanoke Chowan Hospital
Vidant Edgecombe Hospital
Vidant Chowan Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

ECU Health Cancer Care - Eddie and Jo Allison Smith Tower at ECU Health Medical Center
524 Moye Blvd, Greenville, NC 27834
Other Locations
ECU Health Oncology - Kenansville
401 N Main St, Kenansville, NC 28349

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

49 Clinical Trials

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
View 9 Less Clinical Trials

2 Total Publications

Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer".
Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer".
Journal: Internal medicine (Tokyo, Japan)
Published: August 13, 2025
Similar Doctors
Expertise in
5
conditions
Dr. Beng R. Fuh
Hematology | Oncology
Expertise in
5
conditions
Dr. Beng R. Fuh
Hematology | Oncology
Referral may be required

Maynard Children's Hospital At ECU Health Medical Center

2100 Stantonsburg Rd, 
Greenville, NC 
 (0.3 miles away)
252-816-3714
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Beng Fuh is a Hematologist and an Oncologist practicing medicine in Greenville, North Carolina. Dr. Fuh is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Fuh is currently accepting new patients.

Expertise in
35
conditions
Dr. Sameer A. Batoo
Hematology | Oncology
Expertise in
35
conditions
Dr. Sameer A. Batoo
Hematology | Oncology
Referral may be required

Ecu Health Cancer Care-Eddie And Jo Allison Smith Tower At Ecu Health Medical Center

524 Moye Blvd, 
Greenville, NC 
 (0.1 miles away)
252-816-2273
Languages Spoken:
English, Hindi, Kashmiri
See accepted insurances
Accepting New Patients
Offers Telehealth

Sameer Batoo is a Hematologist and an Oncologist practicing medicine in Greenville, North Carolina. Dr. Batoo is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Angiosarcoma, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). Dr. Batoo is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Ecu Health Cancer Care-Eddie And Jo Allison Smith Tower At Ecu Health Medical Center

524 Moye Blvd, 
Greenville, NC 
 (0.1 miles away)
252-816-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Darla Liles is a Hematologist practicing medicine in Greenville, North Carolina. Dr. Liles is highly rated in 39 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Autoimmune Hemolytic Anemia, Bone Marrow Aspiration, and Fasciotomy. Dr. Liles is currently accepting new patients.

Frequently Asked Questions about Dr. Misbah U. Qadir

How do I make an appointment with Dr. Misbah U. Qadir?

You can book an appointment with Dr. Misbah U. Qadir by calling their office at 252-816-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Misbah U. Qadir a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Misbah U. Qadir is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Misbah U. Qadir specialize in?

While Dr. Misbah U. Qadir is a Hematology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Misbah U. Qadir participate in research or clinical trials?

Yes. Dr. Misbah U. Qadir has published 2 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Misbah U. Qadir's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Misbah U. Qadir accept my insurance?

Dr. Misbah U. Qadir accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 252-816-2273 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Qadir's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 20 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile